These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8603068)

  • 1. p16INK4A as a human tumor suppressor.
    Shapiro GI; Rollins BJ
    Biochim Biophys Acta; 1996 Mar; 1242(3):165-9. PubMed ID: 8603068
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
    Elisei R; Shiohara M; Koeffler HP; Fagin JA
    Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A challenge to p16 gene as a major tumor suppressor.
    Marx J
    Science; 1994 Jun; 264(5167):1846. PubMed ID: 8009205
    [No Abstract]   [Full Text] [Related]  

  • 4. P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
    Grimison B; Langan TA; Sclafani RA
    Cell Growth Differ; 2000 Oct; 11(10):507-15. PubMed ID: 11063124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor suppression. Lessons in p16 from phylum Falconium.
    Sheaff RJ; Roberts JM
    Curr Biol; 1995 Jan; 5(1):28-31. PubMed ID: 7697342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-suppressor genes. Open questions on p16.
    Bonetta L
    Nature; 1994 Jul; 370(6486):180. PubMed ID: 8028659
    [No Abstract]   [Full Text] [Related]  

  • 7. Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China.
    Xing EP; Nie Y; Wang LD; Yang GY; Yang CS
    Carcinogenesis; 1999 Jan; 20(1):77-84. PubMed ID: 9934853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele.
    Yarbrough WG; Aprelikova O; Pei H; Olshan AF; Liu ET
    J Natl Cancer Inst; 1996 Oct; 88(20):1489-91. PubMed ID: 8841025
    [No Abstract]   [Full Text] [Related]  

  • 9. Deletion and differential expression of p16INK4a in mouse lung tumors.
    Belinsky SA; Swafford DS; Middleton SK; Kennedy CH; Tesfaigzi J
    Carcinogenesis; 1997 Jan; 18(1):115-20. PubMed ID: 9054597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of a cell cycle regulator in hereditary and sporadic cancer.
    Kamb A
    Cold Spring Harb Symp Quant Biol; 1994; 59():39-47. PubMed ID: 7587092
    [No Abstract]   [Full Text] [Related]  

  • 11. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
    Fujishita T; Mizushima Y; Kashii T; Kobayashi M
    Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of cyclin-dependent kinase 4 inhibitor (p16INK4A/MTS1) gene structure and expression in acute lymphoblastic leukemias.
    Delmer A; Tang R; Senamaud-Beaufort C; Paterlini P; Brechot C; Zittoun R
    Leukemia; 1995 Jul; 9(7):1240-5. PubMed ID: 7630199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53, p15INK4B, p16INK4A and p57KIP2 mutations during the progression of chronic myeloid leukemia.
    Güran S; Bahçe M; Beyan C; Korkmaz K; Yalçin A
    Haematologia (Budap); 1998; 29(3):181-93. PubMed ID: 10069444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CDKN2A (p16) gene and human cancer.
    Foulkes WD; Flanders TY; Pollock PM; Hayward NK
    Mol Med; 1997 Jan; 3(1):5-20. PubMed ID: 9132280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.
    Shapiro GI; Park JE; Edwards CD; Mao L; Merlo A; Sidransky D; Ewen ME; Rollins BJ
    Cancer Res; 1995 Dec; 55(24):6200-9. PubMed ID: 8521414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma.
    Flores JF; Walker GJ; Glendening JM; Haluska FG; Castresana JS; Rubio MP; Pastorfide GC; Boyer LA; Kao WH; Bulyk ML; Barnhill RL; Hayward NK; Housman DE; Fountain JW
    Cancer Res; 1996 Nov; 56(21):5023-32. PubMed ID: 8895759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1.
    Zhang S; Ramsay ES; Mock BA
    Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2429-34. PubMed ID: 9482902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
    Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
    Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational effects on the p16INK4a tumor suppressor protein.
    Yang R; Gombart AF; Serrano M; Koeffler HP
    Cancer Res; 1995 Jun; 55(12):2503-6. PubMed ID: 7780957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel p16INK4A transcript.
    Mao L; Merlo A; Bedi G; Shapiro GI; Edwards CD; Rollins BJ; Sidransky D
    Cancer Res; 1995 Jul; 55(14):2995-7. PubMed ID: 7541708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.